ARTICLE
18 April 2023

White House Report Identifies Precision Medicine For Future R & D Investment

FL
Foley & Lardner

Contributor

Foley & Lardner LLP looks beyond the law to focus on the constantly evolving demands facing our clients and their industries. With over 1,100 lawyers in 24 offices across the United States, Mexico, Europe and Asia, Foley approaches client service by first understanding our clients’ priorities, objectives and challenges. We work hard to understand our clients’ issues and forge long-term relationships with them to help achieve successful outcomes and solve their legal issues through practical business advice and cutting-edge legal insight. Our clients view us as trusted business advisors because we understand that great legal service is only valuable if it is relevant, practical and beneficial to their businesses.
Precision medicine was identified by a recent White House Office of Science and Technology Policy Report ("Report") as a research and development priority for the United States over the next 20 years.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

Precision medicine was identified by a recent White House Office of Science and Technology Policy Report ("Report") as a research and development priority for the United States over the next 20 years. The Report highlighted goals to advance precision medicine, including improvements in health monitoring, multi-omics, cell therapies, artificial intelligence-driven drug development, gene editing, microbial genome sequencing and synthetic biology.

Ten aspiration goals under five broad themes were selected to accelerate medical breakthroughs and advance human health in precision medicine. The five themes are:

Theme 1 - Accessible health monitoring to identify indicators of health and develop and distribute a simple-to-use home diagnostic assay kit to report health across the lifespan and meet the needs of diverse populations.

Theme 2 - Precision multi-omic medicine to collect multi-omic measures in large cohorts with diverse populations, as well as to develop molecular classifications for diagnosis and/or treatment and make these actionable with development of the $1,000 multi-ome.

Theme 3 - Biomanufacturing of cell-based therapies to expand the toolset of technologies used to create cell-based therapies to achieve high viability and targeted delivery at the time of patient administration, as well as expand access to cell-based therapies to decrease health inequities.

Theme 4 - AI-driven bioproduction of therapeutics to increase the speed and diversity of therapeutic manufacturing, including manufacture of current therapeutics as well as design of novel ones.

Theme 5 - Advanced techniques in gene editing to assess current gene-editing systems and emerging technologies for therapeutic gene editing as well as to strengthen the biomanufacturing ecosystem to produce millions of doses of therapeutic gene-editing systems annually.

Report at page 38.

A development and implementation plan to address the research and development needs outlined in the Report will be led by the Office of Science and Technology Policy.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More